Landscapes / Companies
S.Biomedics Co., Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 2
Next date
Neural precursor cells derived from human embryonic stem cell line, Phase 1/2 trial completes
Drugs
2
in active trials · 4 in all
Trials
2 active
4 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | Oct 2028Phase 1/2 trial completes | |||
| Next date | Oct 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Crow's Feet | ||||
| Open drug page | |||||
About
- No active trial
- Allogenic embryonic stem cell-derived A9 dopamine progenitor cell, Clusters of adipose-derived mesenchymal stem cells
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021